论文部分内容阅读
吲哌胺是α-肾上腺素能受体竞争剂,无β阻滞或抗胆碱能作用。据报道应用大剂量吲哌胺对前列腺肥大引起的排尿不畅症状具有缓解作用。本文着重就小剂量治疗良性前列腺肥大进行双盲、平行及多中心研究。 139例良性前列腺肥大有排尿困难症状病人分别来自13个医院,年龄46～84岁。随机分为安慰剂组、吲哌胺20mg(夜间)组、20mg每日二次(下称40mg组)三组。用药4～8周,用药前后进行尿流率等多指标测定。除18例中途停药外,121例用于本研究。结果,治疗8周后,40mg组最高尿流率由基础8.28ml/s增至13.18ml/s(p<0.01);20mg组由9.76ml/s增至12.54ml/s(p<0.05);安慰剂组由11.07ml/s增至12.82ml/s,统计学上无明显差异。但40mg组与安慰剂组最高尿流率有明显差异。
Indapamide is an alpha-adrenergic receptor competitor with no beta block or anticholinergic effects. It has been reported that the application of high-dose indapamine on prostatic hypertrophy caused by symptoms of poor urination have a relieving effect. This article focuses on double-blind, parallel and multicenter studies of low-dose benign prostatic hypertrophy. 139 cases of benign prostatic hypertrophy dysuria patients were from 13 hospitals, aged 46 to 84 years. Randomly divided into placebo group, 20 mg of indapamide (night) group, 20 mg twice daily (hereinafter referred to as 40 mg group) three groups. Medication 4 to 8 weeks, before and after treatment of urine flow rate and other multi-index determination. 121 patients were used in this study, except for 18 stop-hours. Results After 8 weeks of treatment, the highest urinary flow rate increased from 8.28 ml / s to 13.18 ml / s in the 40 mg group (p <0.01), and from 9.76 ml / s to 12.54 ml / s in the 20 mg group (p <0.05) Placebo group increased from 11.07ml / s to 12.82ml / s, no statistically significant difference. However, 40mg group and placebo group the highest urinary flow rate was significantly different.